

LIONHEART
HEALTH
LONGEVITY & WELLNESS
2025
ANNUAL REPORT
INNOVATING TODAY. TRANSFORMING TOMORROW.
HUNTINGTON BEACH, CALIFORNIA
DECEMBER 31, 2025

LETTER TO SHAREHOLDERS

2025: Building the platform for scale

Dear Fellow Shareholders,

2025 was a defining execution year for Lionheart Health. We strengthened financial discipline, expanded clinical infrastructure, advanced our intellectual property estate, secured non-dilutive research funding, and built the operational foundation required to scale our regenerative health and longevity platform.

Our model is increasingly centered on an integrated continuum: clinical innovation and validation, proprietary bioelectric protocols, regenerative aesthetics, health optimization memberships, clinic licensing, and a national eStore designed to extend care beyond the clinic. The objective is to translate technology and clinical learning into repeatable, capital-efficient commercial channels.

The year also brought meaningful external validation. Lionheart was selected as a Top-40 Semi-Finalist in the XPRIZE Healthspan competition, received a $250,000 award, earned multiple UCI Capstone grants, and received industry recognition for micro-stimulator development. Across the broader Lionheart and Leonhardt platform, teams continued gathering clinical data, expanding patent coverage, and building partnerships.

We enter 2026 focused on disciplined commercialization while continuing the research-first approach that created the platform. Our priorities are to expand clinic licensing, launch and grow memberships, scale the eStore, advance structured clinical studies, and continue protecting the intellectual property underlying our bioelectric and regenerative technologies.

Thank you to our team members, clinical collaborators, advisors, shareholders, and partners for their continued commitment.

Howard J. Leonhardt

Founder, Executive Chairman & Co-CEO
Lionheart Health, Inc.

2025 at a glance

$353K	**$250K**	**1,000+**
TOTAL 2025 REVENUE	XPRIZE AWARD FUNDING	PATIENTS IN CUMULATIVE DATASET
700+	**100+**	**Top 40**
IP CLAIMS: ISSUED / LICENSED / PENDING / IN PROCESS	NEW PATENT CLAIMS ADVANCED IN 2025	XPRIZE HEALTHSPAN SEMI-FINALIST

CONTENTS

Annual report structure

01 Regenerative Aesthetics

Skin, hair, joint, sexual health and related regenerative platforms

02 Clinic Licensing & Memberships

Capital-efficient clinic expansion and recurring health optimization programs

03 Health Optimization eStore

National direct-to-consumer channel and clinic lead-generation engine



Lionheart 240 Stimulus™ platform shown in a clinic-style treatment environment. Flagship platform for programmable multi-modality protocols.

04 **Heart & Cardiovascular**
Heart regeneration, circulatory support, blood pressure, vascular and wound programs

05 **Brain Health**
Brain Band™, cognition, mood and neuroregenerative signaling

06 **Major Organ Regeneration**
Whole-body, eye, kidney, bladder, lung, liver, pancreas, hearing and inflammation programs

07 **Cancer**
Bioelectric oncology IP and translational research

08 **Platform, IP & Clinical Data**
Bioelectric protein expression, Klotho, biologics, alliances and selected datasets

09 **Financial Review**
2022-2025 summary and 2026 strategic targets

10 **Governance & Forward-Looking Statements**
Corporate information and risk-aware disclosure

EXECUTIVE OVERVIEW

One platform. Multiple pathways to healthier longevity.

Lionheart Health combines bioelectric stimulation, regenerative signaling, diagnostics, device-enabled therapy, selected biologic approaches, and structured lifestyle support. During 2025, the company concentrated on clinical data expansion, intellectual property, partnerships, and preparation for recurring-revenue commercialization.

Financial discipline

Year	Operating Revenue	Grant Income	Total Revenue	Operating Expenses	Net Loss
2022	$0	$0	$0	$77,232	~$(76,000)
2023	$24,569	$0	$24,569	$668,812	$(644,243)
2024	$77,840	$0	$77,840	$964,681	$(965,551)
2025	$103,000	$250,000	$353,000	$746,604	$(675,604)

Management reports that the 2025 net loss improved by approximately 30% from 2024 while capital remained concentrated on R&D, regulatory work, clinical protocols and intellectual property. These figures are presented as management-prepared annual-report information and are not represented here as audited financial statements.

Commercial architecture

- Clinic licensing: full-scale and specialty clinic models supported by equipment, training, SOPs, centralized support and royalties.
- Health Optimization Memberships: biomarker testing, AI imaging alliances, personalized supplements and integrated protocol planning designed for recurring engagement.
- Health Optimization eStore: at-home devices, therapy kits and complementary products designed both for direct revenue and lower-cost customer acquisition.
- Clinical and research platform: continued data collection across bioelectric, regenerative, organ-specific and whole-body programs.

SECTION 01

Regenerative Aesthetics

Regenerative aesthetics was one of Lionheart's most clinically active and commercially developed groups in 2025, spanning skin, hair, joint health, sexual wellness, body composition and other appearance- and function-oriented protocols.

Core platforms

Platform	2025 position	Selected reported data / direction
SkinStim™	Clinical platform	Reported reductions in wrinkle depth and inflammation with increases in elasticity, collagen density and circulation.
HairCell™	Multi-site clinical and commercial expansion	Multi-site work reported hair-density improvement; strategic deployment relationship established with GetHairMD.
OrthoStim™	Joint health studies	Reported pain reduction, mobility improvement and no serious adverse events in the summarized dataset.
ErectiStim™	100+ patient clinical dataset	Reported improvement across erectile-function measures with no serious adverse events in the summarized studies.
FemStim™	Development	Female sexual wellness counterpart planned for further clinical study.
TestiStim™	Development / pilot data	Program focused on male vitality and hormone-related measures.
Stem Cell Bra™	Pilot development	Prior animal and clinical pilot work; further pivotal-study planning described.

HairCell™: clinic + home strategy

Lionheart entered a strategic commercial relationship with GetHairMD to expand HairCell™ bioelectric scalp therapy through an established clinic network. The commercial design combines clinic device placement, service royalties and co-development of an at-home treatment cap.

100
2026 HAIRCELL STIMULATOR PLACEMENT TARGET

7%
SERVICE ROYALTY STRUCTURE DESCRIBED

50/50
DTC CAP CO-DEVELOPMENT STRUCTURE

Selected aesthetics data

Program	Selected management-reported outcome ranges
SkinStim™	Wrinkle depth ↓22–38%; elasticity ↑18–35%; collagen density ↑20–40%
HairCell™	Hair density ↑15–32%; shaft thickness ↑12–28%; shedding ↓25–45%
OrthoStim™	VAS pain ↓42–58%; 6-minute walk ↑12–22%; ROM ↑10–18%
ErectiStim™	IIEF ↑35–62%; erection duration ↑40–75%; hemodynamic flow ↑18–35%

SECTION 02

Clinic Licensing & Memberships

Lionheart's commercialization strategy is designed to expand access without requiring company ownership of every treatment location. The licensing model pairs proprietary protocols and equipment with training, operating procedures and centralized support.

Licensing model

- Full-scale Lionheart Longevity clinic licenses
- Specialty licenses for hair, skin, vision, sports medicine, EMS fitness, weight loss, bladder/urology and related categories
- Equipment bundles and royalty economics
- Training, SOPs and centralized commercial support

Health Optimization Membership

Preparation for the Lionheart Health Optimization Membership Program accelerated in 2025 for a broader 2026 launch. The intended model moves customer relationships from episodic procedures toward recurring measurement, planning and optimization.

460+	AI MRI	Recurring
BIOMARKER TESTING INTEGRATION	IMAGING ALLIANCE	MEMBERSHIP REVENUE FOUNDATION

2026 operating targets

Growth engine	2026 target stated in management plan
Full clinic licenses	25 operating
Specialty clinics	75 operating
Active memberships	1,000

SECTION 03

Health Optimization eStore

The Lionheart Health Stim eStore is intended to function as both a national sales channel and a customer-acquisition engine. During 2025, the company expanded SKUs, bundled therapy kits, at-home continuation products and digital marketing capability.

The eStore flywheel



Lionheart 240 Stimulus™ - flagship bioelectric stimulation platform and central device within the Lionheart protocol ecosystem.

- Acquire customers with health, wellness and aesthetic products.

- Build a database of consumers already investing in health improvement.
- Introduce qualified customers to higher-ticket proprietary Lionheart programs.
- Direct customers to nearby licensed clinics where appropriate.
- Extend clinic protocols into the home through continuation devices and products.

Higher-value pathways

eStore entry point	Potential Lionheart pathway
Hair / scalp products	HairCell™ clinic and at-home programs
Skin / aesthetics	SkinStim™ and regenerative aesthetics
Fitness / muscle	BodStim™ and Health Optimization Membership
Joint support	OrthoStim™
Sexual wellness	ErectiStim™ / FemStim™
Healthy aging	KLOTHO-UP™ and membership ecosystem

Management previously described an aspirational eStore run-rate of more than $250,000 per month by December 2026. This earlier channel ambition should not be interpreted as the current consolidated 2026 revenue target. The revised company-wide revenue target is $650,000 for 2026, followed by $13.4 million for 2027; both are forward-looking and subject to execution and financing.

SECTION 04

Heart & Cardiovascular

The cardiovascular portfolio combines regenerative medicine, circulatory-assist technology, vascular stimulation, blood-pressure programs and wound-healing development.

Platform	2025 progress
BioLeonhardt LTP	UCI Capstone recognition; new heart-regeneration patent claims; preparation for GLP large-animal work and future OUS pilot study.
Valvublator, Inc.	Benchtop testing and next-generation design work completed; animal studies planned.
PressureStim LTP	Pilot OUS clinical studies completed, including work with BodStim™.
VascuStim LTP	Wound-healing clinical development and collaboration with ElectroMedical Technologies.
BioPace / AortaCell / VibroCell	IP and technical development continued.

Selected clinical signals

Program	Selected management-reported data
PressureStim™	Systolic BP ↓12–18 mmHg; diastolic BP ↓6–10 mmHg; no serious adverse events reported.
VascuStim™	Mexico and Czech cohorts reported improvements in wound size, pain and perfusion measures.
Bioheart / BioLeonhardt	Historical summary cites 84% of treated heart-failure patients improving vs. 16% placebo.

Across cardiovascular programs, the team is also investigating Klotho elevation and its potential relationship to vascular health within the broader KLOTHO-UP research framework.

SECTION 05

Brain Health

Brain Band™ is the lead platform in Lionheart's brain-health group. 2025 activity included continued clinical validation, product development, a UCI Capstone grant, and integration into the KLOTHO-UP Healthspan research program.

Brain Band™ development

- Pilot clinical work in Brazil following encouraging preclinical work
- Combined Brain Band™ and BodStim™ observations involving cognition, memory and mood
- UCI Capstone engineering support for product enhancement
- Bioelectric IP involving GDF10, BDNF and Klotho signaling

Selected management-reported outcomes

Measure	Reported range
Memory recall	↑18–34%
Working memory	↑15–28%
Processing speed	↑12–22%
Executive function	↑14–26%
Depression score	↓25–45%
Anxiety score	↓18–35%
Mental clarity	↑30–50%
Overall responder rate	~80–88% in at least one major parameter

SECTION 06

Major Organ Regeneration

Lionheart's major-organ portfolio is built around organ-specific bioelectric signaling and integrated regenerative approaches. In 2025, development continued across whole-body regeneration, vision, kidney, bladder, lung, liver, pancreas, hearing, inflammation and joint health.

Whole-body regeneration

Development advanced on KLOTHO-POD II, described as a non-invasive platform, and KLOTHO-POD III / LIONHEART OCTOPUS, described as an implantable concept. The company also advanced research and intellectual property around bioelectric-enhanced peptide uptake and Klotho nanoflowers.

Organ-specific programs

Program	2025 / next-step status
EyeCell™	IRB-approved U.S. study enrollment; prior pilot observations supported continued study.
KidneyCell™	U.S. study preparation following Brazilian pilot safety and efficacy work.
BladderCell™ / B-Alive™	Wearable version developed; additional studies planned after OUS work.
EarCell™	Combination hearing-recovery study planned.
RegenaLung™	IP and development planning continued.
LiverCell™	IP and development planning continued.
PancreaCell™	IP and development planning continued.
InStim™	Inflammation-focused protocol development supported by issued patent claims.
BodStim™	Two Brazilian studies completed; U.S. registry work and KLOTHO-UP integration.

External validation

Top 40
XPRIZE HEALTHSPAN

$250K
XPRIZE AWARD

Multiple
UCI CAPSTONE GRANTS

SECTION 07

Cancer

CancerCell, Inc. and the broader Leonhardt platform hold or license a portfolio of bioelectric cancer-treatment intellectual property. The 2024-2025 research focus included investigation of Klotho's tumor-suppressive properties and preparation for additional animal studies following a UCLA feasibility study with mixed results.

Selected issued / pending technologies

Technology	Patent / status	Primary concept
Tumor Therapy - Multi-Modality Bioelectric Treatment	US 11,185,691	Tumor electrical reading and customized signal delivery; immune, angiogenesis and regenerative components.
Rapid Destruction of Malignant Tumors	US 9,707,403 / 9,636,507 / 9,440,083	Bioelectric excitotoxicity and osmotic-shock approaches.
Encoded Bioelectronic Cancer Cell Apoptosis	US 9,492,478 / 9,295,835	Encoded electrical protocols intended to trigger apoptosis.
Bioelectric Cancer Cell Signal Processing	US 9,032,964	Cancer-cell electrical signal processing for therapy.
Bioelectric Cancer Treatment System	US 8,831,738	Electrical / EMF signal approach intended to induce apoptosis.
Bioelectric OPG Cancer Treatment	Application 20200330759 - pending	OPG modulation involving RANK/RANKL pathways.

These programs remain research and development activities. Any therapeutic claims require appropriate clinical validation and regulatory authorization before commercial medical use.

PLATFORM

Intellectual Property & Regenerative Signaling



Lionheart 240 Stimulus™ / Stimulus Force platform - programmable multi-channel stimulation hardware used as a foundation for selected Lionheart protocols.

Lionheart's platform strategy centers on controlled bioelectric signaling intended to influence endogenous regenerative proteins and to complement selected regenerative biologics. Management reports more than 100 new patent claims filed or advanced during 2025 and more than 700 total claims issued, licensed, optioned, pending, in process or otherwise within the described estate.

IP / platform	Status described	Focus
GDF10 & BDNF modulation	Issued	Brain regeneration / neurorepair signaling
Klotho expression	Issued	Longevity and organ-regeneration signaling
Follistatin modulation	Issued	Muscle regeneration / anti-atrophy
COL17A1 modulation	Issued	Skin regeneration and matrix support
Inflammation modulation	Issued	Targeted inflammatory signaling
SIRT / SESTRINS / NANOG	Issued / pending	Longevity, stemness and metabolic resilience
Klotho nanoflowers	Provisional filed	Klotho delivery combined with bioelectric signaling
Bioelectric-enhanced peptides	Provisional filed	Peptide uptake / signaling enhancement
Klotho-expressing stem cells in nutrient hydrogel	Patent pending	Cell-based Klotho delivery in nutrient scaffold
Bioelectric-enhanced exosomes & secretomes	Provisional filed	Regenerative signaling enhancement

ECOSYSTEM

Strategic Alliances

Lionheart expanded collaborations across diagnostics, imaging, supplements, regenerative biologics, device manufacturing and clinical delivery. These relationships are intended to deepen the platform, accelerate development and reduce the need to vertically integrate every component.

Alliance / partner	Role described in 2025 materials
Generation Lab	460+ biomarker testing
Jinfiniti Labs	Klotho testing, NAD-related products and laboratory support
CoreViva	AI MRI alliance
SNIP Nutrigenomics	Personalized supplement mixes
Rejuvant	Ca-AKG supplement partner
Mettler Electronics	Device manufacturing / supply relationship
ElectroMedical Technologies	Device / wound-healing collaboration
Saebo	Rehabilitation technology relationship
Axiobionics	Stimulation / rehabilitation relationship
SynovaLife	Adipose tissue bedside processing platform
HTM Electronics	Skin, hair, body, BP, sexual health, joint and veterinary device categories
Wiemspro	EMS suit technology
GetHairMD	HairCell™ clinic deployment and DTC co-development

CLINICAL DATA

Selected 2025 Clinical Data Summary

The following ranges reproduce management's annual-report summaries. They combine datasets at different stages of development and should not be interpreted as results from one standardized, randomized pivotal trial. Where programs remain investigational, results require further confirmation.

Product / program	Selected outcome summary
BodStim™	+10–30% muscle/metabolic gains; Klotho increases reported in summarized studies
OrthoStim™	Pain ↓40–65%; improved mobility and range of motion
ErectiStim™	89% improvement rate reported across major measured parameters
PressureStim™	Blood-pressure reductions reported in pilot work
VascuStim™	Perfusion and wound-healing improvements reported
BladderCell™	Urinary symptom improvements reported
EyeCell™	Vision-function improvements reported in early datasets
SkinStim™	Wrinkle/inflammation reductions; collagen/elasticity improvements reported
HairCell™	Hair-density improvements reported in multi-modality studies
Brain Band™	Cognitive and mood improvements reported across selected measures

HEALTHSPAN

KLOTHO-UP™ and the Healthspan Platform

KLOTHO-UP™ is the integrative research framework connecting Lionheart's whole-body stimulation, diagnostics, nutrition, supplements and organ-specific programs. Lionheart's selection as a Top-40 Semi-Finalist from more than 600 XPRIZE Healthspan entries was a major 2025 milestone.

Integrated components described

- BodStim™ whole-body stimulation
- Brain Band™
- Klotho and broad biomarker testing
- AI MRI imaging alliance
- Personalized nutrition and supplements
- Targeted organ-specific bioelectric protocols
- Selected regenerative biologics in appropriate research / OUS settings

1st Annual Klotho Conference - 2025

Lionheart also hosted an inaugural Klotho-focused scientific and clinical conference bringing together physicians, researchers, bioelectric specialists, nutrigenomics experts and longevity innovators. Topics included Klotho biology, bioelectric stimulation-induced expression, metabolic optimization, stem-cell homing and regenerative signaling.

RECOGNITION

LEADERSHIP & TEAM

People Behind the Lionheart Platform

Lionheart Health combines executive leadership, medical and scientific expertise, engineering, research, operations, marketing, sales and financial advisory experience. The following team section summarizes principal roles and contributions reflected in the company materials.

TEAM MEMBER	ROLE	PRINCIPAL CONTRIBUTION
Howard J. Leonhardt	Executive Chairman & Co-CEO	Founder; corporate strategy; principal inventor and IP development; product/platform conception; financing, partnerships, licensing and company leadership.
Scott Hoots	Co-CEO	Commercial execution; operating strategy; clinic and licensing expansion; partnerships; sales organization and scaling business operations.
Dr. Leslie Miller	CMO & Board Director	Medical strategy; clinical protocol development; physician engagement; clinical-study design and oversight; scientific and regulatory guidance.
Brian Lasater	CTO	Device engineering; systems integration; product development and technical execution; 40 years of medtech electronics experience.
Dr. Jorge Genovese	VP Bioelectric Research	Bioelectric medicine R&D; regenerative research; translational development; mechanism and protocol development.
Dr. Sanjay Bhojraj	Chief Functional Health Officer / Newport Beach MedSpa Director	Functional-health protocols; clinical implementation; longevity and cardiovascular expertise; MedSpa medical leadership.
Kelsie Leonhardt	Chief Neuroscientist, MedSpa Operations & Business Development	Neuroscience programs; clinical program development; MedSpa operations; business development and strategic growth.
Brian Hardy	Director of Marketing	Brand development; marketing campaigns; customer acquisition and go-to-market support; long-term Leonhardt team experience.
Jasmine Arredondo	Chief Accountant / Accounts Payable	Accounting operations; accounts payable; financial administration and institutional financial knowledge.
Lynn Hammerschmidt	KlothoYears Director / Senior Marketing Consultant	KlothoYears program development; marketing, messaging, customer outreach and commercialization support.
Henk Abbink	VP International Market Development	International business development; clinic and licensing partnerships; global market expansion.
Tessa Sphar	Licensee Onboarding Specialist	Licensee onboarding; training coordination and clinic-launch preparation.
Matt Fendrich	Sales Development Consultant	Sales pipeline development; commercial outreach and medical-device business development.
Dr. Cristiane Carboni	Research Coordinator - Brazil	Clinical research coordination; study support and scientific collaboration in bioelectric and regenerative protocols.
James Dorsey	Chief MedSpa Advisor	MedSpa operating strategy; clinical-service development; clinic growth and commercialization advice.
John Judd	Senior Financial Advisor	Strategic planning; capital formation and financial decision support.
Scot Jordan	Senior Financial Advisor	Corporate finance; growth planning and business strategy.
Kurt Kruger	Senior Financial Advisor	Financial structuring, analysis, capital-markets strategy and long-term financial planning.
Jeremy Koff	Business Development Advisor	Partnerships, strategic relationships, commercialization and medtech/neurotechnology business development.
Laura Bem	Head of Customer Service & MedSpas Manager	Customer service; clinic operations; customer experience and MedSpa management.
Jon Dillon	Director, West Coast Sales Development / OrthoStim(TM) Sales Leader	West Coast sales development; OrthoStim(TM) sales; clinic relationships and market expansion; 40 years of sector experience.
Dave Whitney	Senior MedSpa Marketing Advisor	MedSpa marketing strategy, customer acquisition, brand positioning and clinic growth; 15 years of

		sector experience.
Suhani Khandelwal	Research Coordinator & Biostatistician	Clinical and scientific research coordination, data management, statistical analysis and interpretation for scientific, regulatory and investor review.

Scientific & Clinical Advisory Board

The broader advisory board provides strategic, scientific, clinical, engineering, translational and commercialization guidance. Advisory participation does not imply day-to-day operational authority or direct patient care unless separately contracted.

Dr. Doris Taylor - Scientific Advisory Board Co-Chair	**Dr. Stuart Williams - Scientific Advisory Board Co-Chair**	**Dr. Dipti Itchhaporia - Senior Medical Advisor**
Dr. Timothy Henry - Senior Medical Advisor	Camillo Ricordi	Harold Ott
Race Kao	Joel Aronowitz	Juan Chachques
Felipe Prosper	William Abraham	Barry Greenberg
Stephen Ellis	Stephen Ramee	Warren Sherman
Nicolas Chronos	Ron Waksman	Zvonimir Krajcer
Joseph Maroon	Rodrigo Plentz	Mark Kroll
Michael Levin	Keith March	Marc Penn
Catherine Davies	Allyson Berkey	Samer Banihani
Patrick Sewell	Bors Schwartz	Denis Pena
Jared Szymanski	Meena Verma	Ramona Braganza
Scott Marland	James Moore	Ghassan Kassab

Contribution diligence note. For CPA and investor diligence, contribution schedules should separately document cash invested or advanced, deferred or unpaid compensation, intellectual property contributed, services/time contributed, and measurable deliverables. The public/team materials do not by themselves establish dollar values or accounting treatment.

Awards & External Validation

Recognition	2025 significance
XPRIZE Healthspan Top-40 Semi-Finalist	Selected from more than 600 global entries
$250,000 XPRIZE award funding	Non-dilutive research award included in 2025 total revenue
Innovator of the Year Finalist	Orange County Business Journal
Life Sciences Technology Company of the Year Finalist	Octane
Micro Stimulator Developer of the Year	MedTech Outlook
Multiple UCI Capstone Grant Awards	Engineering support for Brain Band™, Lionheart Octopus / BioLeonhardt and whole-body / KlothoPod work
AbbVie / Allergan ULP Innovation Award	Prior 2023 recognition supporting the platform's innovation history

FINANCIAL REVIEW

2025 Financial Summary

$103K	$250K	$353K
OPERATING REVENUE	GRANT INCOME	TOTAL REVENUE
$746.6K	**$(675.6K)**	**~30%**
OPERATING EXPENSES	NET LOSS	YOY NET-LOSS IMPROVEMENT

The annual-report materials state that the majority of capital was deployed into R&D, regulatory advancement, clinical protocols and IP protection. Management characterizes 2025 as a shift from infrastructure-heavy spending toward scalable revenue engines and more disciplined capital deployment.

2026 strategic targets

Priority	Management target
Clinic licensing	25 full clinic licenses + 75 specialty clinics operating
Memberships	1,000 active memberships
eStore	More than $250,000 monthly sales by December 2026
XPRIZE	Advance toward finalist milestones
Intellectual property	Add 100 patent claims
Clinical data	Add data on 100+ additional patients
Capital	Raise more than $3 million in growth capital
Total revenue	$650,000 target for 2026; $13.4 million target for 2027, both subject to execution and financing

All 2026 targets are forward-looking and subject to financing, regulatory, clinical, operational, market and execution risks.

CORPORATE INFORMATION

Governance, Facilities & Disclosure

Operating locations

Function	Location
Offices & Warehouse	21060 Pacific City Circle #6115, Huntington Beach, CA 92648
R&D Lab	5270 California Avenue, Irvine, CA 92617
Research Clinic & Training Center	4440 Von Karman, Suite 100, Newport Beach, CA 92660

Annual shareholder meeting

The annual shareholder meeting is expected to be rescheduled for fall 2026. Formal notice will be provided when the date and meeting arrangements are approved.

Forward-looking statements

This Annual Report contains forward-looking statements, including statements regarding anticipated clinical studies, regulatory pathways, commercialization, partnerships, product launches, clinic licensing, membership growth, eStore sales, financing, revenue targets, intellectual property, and future development. These statements reflect current expectations and involve known and unknown risks and uncertainties. Actual results may differ materially because of factors including financing availability, regulatory review, clinical outcomes, product development, manufacturing and supply, intellectual-property matters, competition, reimbursement, market acceptance, execution risk and general economic conditions.

No forward-looking statement is a guarantee of future performance. Investigational technologies and protocols described in this report may not be approved for commercial medical use in the United States or other jurisdictions. References to OUS activity mean outside the United States. Clinical observations and pilot results may not predict results in larger, controlled studies.

About this report

This 2025 Annual Report is a shareholder and stakeholder progress report prepared from Lionheart Health management materials. It is designed in the style of a modern healthcare-company annual report while retaining Lionheart's portfolio-group structure. It is not a substitute for any registration statement, audited financial statements, SEC filing, offering document or other legally required disclosure.

INVESTOR PORTAL SUPPLEMENT

Public-company-style annual disclosure and claim-verification schedule | Prepared October 2026

STATUS OF THIS DOCUMENT

This is a company-prepared 2025 annual progress report using a public-company annual-report presentation format. It is not a filed Form 10-K, a registration statement, an auditor's report, or an opinion on regulatory clearance. The 2025 financial figures are management-reported and have not been independently audited for purposes of this publication. No audit opinion is expressed.

PART I — BUSINESS AND RISK FACTORS

Item 1. Business model and operating segments

The seven reporting groups presented in this report are strategic business areas, not necessarily operating segments under ASC 280: (1) Regenerative Aesthetics, (2) Clinic Licensing & Memberships, (3) Health Optimization eStore, (4) Heart & Cardiovascular, (5) Brain Health, (6) Major Organ Regeneration, and (7) Cancer. The 240 Stimulus™ platform is presented as a flagship product, followed by BodStim™, KlothoPod II™, SynovaWave™, BioPRF, and therapy accessories. Product images and renderings do not establish FDA authorization for particular uses.

Item 1A. Principal risk factors

- Early-stage commercialization and financing: The company has incurred losses and may require additional financing; future revenues, licenses and memberships may not materialize as forecast.
- Clinical evidence: Management summaries combine small studies, preliminary observations, external literature, and partner-reported data; endpoints, controls, sample sizes, adverse events and independent replication vary.
- Medical-device and biologics regulation: Clearance of a predicate or base device does not itself clear every new indication, accessory, protocol or biologic combination. IRB approval does not constitute FDA marketing authorization.
- Intellectual property: Patent applications, provisional filings, licenses, options and issued claims confer different rights. Counts of claims do not establish validity, enforceability or freedom to operate.
- Partner and supply-chain concentration: Commercial terms, device availability, clinical site performance, international approvals and third-party dependencies may change.
- Liquidity, governance and disclosure: Investor disclosures remain subject to reconciliation with accounting records, cap table, agreements, related-party transactions, litigation and audited financial statements.

PART II — MANAGEMENT DISCUSSION AND FINANCIAL REVIEW

Item 7. Management's discussion and analysis (MD&A)

Management reports 2025 operating revenue of $103,000 and $250,000 of XPRIZE-related funding, for $353,000 of total reported revenue. Classification of award funding as grant income or revenue, recognition timing and applicable accounting policy require CPA review. Management reports a 2025 net loss of $675,604 compared with $965,551 in 2024, a decrease in reported net loss of approximately 30.0%. The stated 2025 operating expenses of $746,604 do not directly reconcile to the stated $675,604 net loss from the displayed revenue components alone; other income/expenses, cost of revenue, classifications and accounting adjustments must be reconciled to the trial balance before audit-ready publication.

The revised 2026 revenue target of $650,000 and 2027 revenue target of $13.4 million, clinic-license targets, eStore monthly-sales objectives and device placements are management projections rather than achieved 2025 results. The reported $3 million capital need is a funding assumption, not committed financing.

Results of operations—2025 compared with 2024

Management reports $353,000 in total 2025 revenue and grant-related funding, comprising $103,000 of operating revenue and $250,000 of XPRIZE Healthspan award funding. The comparative 2024 operating revenue figure in the supplied management schedule was $77,840. Operating revenue therefore increased $25,160, or approximately 32.3%. Because grant recognition and accounting classification have not been independently verified, the award should be shown separately from customer-generated operating revenue pending CPA review.

Operating costs and net loss

The supplied 2025 financial schedule lists operating expenses of $746,604 versus $964,681 in 2024, a decline of $218,077 (approximately 22.6%). Management reports net losses of $675,604 in 2025 and $965,551 in 2024, an improvement of $289,947 (approximately 30.0%). These amounts are unaudited and may be affected by other income, grant treatment, noncash items, accruals and period-end adjustments. A complete reconciliation to the general ledger and audited statements is required before SEC-style financial disclosure.

Revenue drivers and commercial development

During 2025 the company concentrated on developing multiple commercial channels: clinic and specialty licensing, membership programs, proprietary stimulation equipment, regenerative aesthetics protocols, and a direct-to-consumer eStore. The flagship Lionheart 240 Stimulus™ platform and BodStim™ EMS offering are central to the product-led strategy. Management describes GetHairMD as a prospective clinic-channel distribution relationship; device deployment targets, royalty rates, purchase commitments and cash collections require confirmation against executed agreements and accounting records.

Liquidity, capital resources and financing requirements

The business remained loss-making in 2025 and its planned scale-up depends on sufficient liquidity, financing and cash collections. Management stated a goal of raising more than $3 million for marketing, staffing, inventory, clinic deployment and clinical data collection. The supplied materials do not include comparative balance sheets,

a cash-flow statement, cash balance, debt maturity schedule, accounts receivable aging or committed financing availability. Accordingly, no cash runway or liquidity sufficiency conclusion can be made from this report.

Research, product development and clinical data

Development spending and personnel efforts supported programmable bioelectric stimulation, Klotho-associated signaling, multi-modal wellness protocols, device integration and the preparation of clinical studies. Management reports more than 1,000 treated patients across historical programs; this aggregate is not equivalent to enrollment in a single controlled trial. Clinical result ranges are exploratory, span different cohorts and may include third-party findings. The next phase prioritizes defined endpoints, standardized case report forms, consistent adverse-event capture, statistical plans and independently reviewable study datasets.

Intellectual property—issued, pending and optioned rights

Management describes a portfolio exceeding 700 patent claims across issued patents, pending applications, provisional filings, licensed or optioned rights and inventions in preparation. These are not interchangeable legal categories; a claim in a pending application is not an issued enforceable claim. The company reports more than 100 claims filed or advanced during 2025, including programs involving Klotho, BDNF/GDF10, Follistatin, stem-cell homing, biologics and targeted stimulation. Patent-family-by-family verification should identify jurisdiction, application number, issue status, maintenance fees, ownership, license scope, encumbrances and expiration. Cancer-related rights subject to options or performance terms should not be portrayed as owned patents.

Personnel, infrastructure and readiness for the next stage

During the build-and-scale phase, Lionheart expanded leadership, clinical coordination, engineering, finance, marketing, business development and advisory capabilities. The operating model includes the Huntington Beach corporate base, Irvine research laboratory and Newport Beach clinic/training site. Management's next-stage priorities include accountable functional ownership, audited financial reporting, regulatory documentation, training SOPs, vendor qualification, customer-support systems, centralized clinic onboarding and repeatable sales processes. Staffing descriptions reflect the management roster provided for the report and do not establish that every individual was an employee throughout 2025.

2026 outlook and material uncertainties

Management's historical 2026 objectives included 25 full-clinic licenses, 75 specialty clinics, 1,000 memberships, $250,000 in monthly eStore sales by year-end, additional clinical data and a revised $650,000 total revenue target for 2026, with $13.4 million targeted for 2027. These are aspirational targets, not contractual backlog or guidance supported by a disclosed financial model. Actual performance depends on financing, product supply, medical-device and biologics regulatory requirements, reimbursement and customer adoption, intellectual property rights, partner execution and clinical outcomes.

Critical accounting estimates and information gaps

The company should document revenue recognition for device shipments, license fees, subscriptions, royalties, grants and bundled services; inventory valuation and obsolescence; capitalization versus expensing of R&D and patent costs; share-based compensation; related-party transactions; deferred compensation; and going-concern evaluation. No opinion is expressed here on conformity with U.S. GAAP. The financial schedules in this report are management-prepared and not a substitute for audited statements and footnotes.

Item 8. Financial statements and supplementary data

The summary table in the body of the report is unaudited management information. A complete public-company financial statement package would ordinarily include comparative balance sheets, statements of operations, stockholders' equity and cash flows, significant accounting policies, notes, auditor reports where required, and disclosures of subsequent events and related-party transactions. These are not supplied in the source materials and have not been fabricated.

PART III — LEADERSHIP AND GOVERNANCE

CLAIM VERIFICATION AND RELEASE CONTROLS

The following is an editorial verification schedule. "Management-reported" means repeated from the supplied company report, not independently substantiated. "Documentation required" means investor-portal publication should link or retain the underlying source evidence. "Independent literature" must not be presented as a Lionheart clinical outcome.

CLAIM	DISCLOSURE STATUS	EVIDENCE TO RETAIN
2025 $353,000 total reported revenue; $103,000 operating; $250,000 XPRIZE funding	Management-reported; CPA reconciliation required	General ledger, grant agreement, award recognition, trial balance
2025 net loss $(675,604) vs 2024 $(965,551)	Management-reported; financial reconciliation required	2024/2025 audited financial statements and expense detail
700+ patent claims; 100+ claims added in 2025	Documentation required	Patent family schedule, patent numbers, application status, claims count by family, license and option agreements
XPRIZE Top-40 selection and $250,000 award	Documentation required	Official XPRIZE announcement and award documentation
1000+ cumulative patients; multiple efficacy ranges	Preliminary / heterogeneous; not independently verified	Protocol, enrollment log, consent, endpoint definitions, statistical plan and signed study reports
EyeCell, OrthoStim, ErectiStim, Brain Band and other treatment outcome percentages	Management-reported, not established pivotal efficacy	Study-level source tables, n, comparator, follow-up, adverse events, and IRB identifiers
FDA clearance, NSR determinations and IRB approval	Indication-specific review required	510(k) clearance letters, device labeling, IRB approvals, FDA correspondence
Cancer patent rights and exclusive option	Contractual scope requires confirmation	Executed agreements, assignments, performance conditions and counsel review
GetHairMD royalty, deployments and DTC cap joint venture	Contractual claims require verification	Signed commercial agreement, amendments and shipment records
Awards, alliance descriptions and partner capabilities	Documentation required	Dated press releases, award letters, partner agreements and permissions
2026 targets, XPRIZE finalist outcome, $650,000 2026 revenue target and $13.4 million 2027 target	Forward-looking projections only	Board-approved operating plan and updated assumptions

Regulatory interpretation

FDA's January 2026 General Wellness guidance addresses low-risk products promoting healthy lifestyles and does not establish clearance for disease-treatment indications or combination products. Marketing claims should be

reviewed against each product's intended use, labeling and applicable authorization. Reference: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices

Disclosure and assurance limitations

All clinical ranges and research outcomes in the main report are attributed to management-provided summaries unless accompanied by a specific primary study citation. The report should not be represented as externally validated clinical efficacy, an audited financial report, or an SEC-compliant Form 10-K. Figures, IP statuses, regulatory descriptions and forward-looking claims should be approved by finance, regulatory, clinical, legal and executive reviewers before posting.

Investor Portal | Verification and Publication Notes

Prepared October 2026 from management-supplied 2025 annual progress materials. This is a voluntary shareholder annual report in public-company style, not a Form 10-K, SEC registration statement, audited financial statement, or independent assurance report.

Financial presentation

Management reported $353,000 in 2025 total revenue/funding, consisting of $103,000 in operating revenue and a $250,000 XPRIZE award, and a $675,604 net loss. Classification and recognition of the XPRIZE award as revenue versus grant or other income requires accounting review. Financial schedules have not been independently audited or reconciled in this publication.

Clinical evidence and regulatory claims

Clinical percentage ranges and responder figures are company-supplied summaries spanning different protocols and populations. Without underlying study reports, sample sizes, statistical analyses, controls and follow-up periods, they should not be construed as proven treatment efficacy. IRB approval authorizes a study protocol, not FDA marketing clearance for its investigated indications. Clearance or authorization of a component device does not automatically extend to new intended uses, combinations, or biologics.

Intellectual property and commercial agreements

Patent counts, grant status, exclusive rights, options, royalty percentages, and partner deployment forecasts require reconciliation to patent-office records and executed agreements. Pending claims are not issued patent rights. License options are not exercised licenses. Forecast deployments are not completed sales.

Forward-looking statements

2026 objectives, revenues, clinical enrollment, expansion, financing and regulatory milestones are targets, not historical outcomes or guarantees. Actual results may differ materially because of funding, clinical, regulatory, manufacturing, sales execution, intellectual property, reimbursement and other risks.

Publication checklist

- Obtain CPA-reviewed 2024–2025 financial statements, accounting policies, balance sheets and cash-flow statements.
- Confirm the XPRIZE award documentation and financial recognition treatment.
- Match patent claims, titles, grant status and ownership to a dated patent-family schedule.
- Verify every outcome percentage against source study reports and label as preliminary where appropriate.
- Confirm product-specific FDA clearances, investigational uses and foreign-jurisdiction permissions.
- Confirm executive titles and dates of service, partner rights and material commercial terms.
- Obtain legal and management sign-off before public investor-portal publication.

LIONHEART HEALTH, INC.

Corporate headquarters

21060 Pacific City Circle, Unit 6115
Huntington Beach, California 92648

Research and operating locations

Research laboratory: 5270 California Avenue, Irvine, California 92617
Research clinic and training center: 4440 Von Karman Avenue, Suite 100, Newport Beach, California 92660

Investor information

www.lionheartlongevity.com | www.lionhearthealthstim.com

Report status and availability

Company-prepared annual progress report for the year ended December 31, 2025. Management-reported financial figures are unaudited. This document is not an SEC-filed Form 10-K and should not be construed as an audited financial statement, regulatory authorization, or an offer to sell securities. Investors should review the risk factors, financial limitations, and forward-looking statement disclosures contained herein.

The annual shareholder meeting date will be communicated separately when rescheduled.

© 2026 LIONHEART HEALTH, INC. • ALL RIGHTS RESERVED